Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has announced that the Singapore Health Sciences Authority (HSA) has approved the interim authorization of its mRNA vaccine against COVID-19 (COVID-19 Vaccine Moderna) for use under the Pandemic Special Access Route (PSAR).

“Today’s authorization is another important step in the global fight against COVID-19,” said Stéphane Bancel, Chief Executive Officer of Moderna. “I want to thank the Singapore Ministry of Health and the HSA for their collaboration and for the confidence they have demonstrated in COVID-19 Vaccine Moderna with this decision.”

The Singapore Ministry of Health has secured access to COVID-19 Vaccine Moderna through a supply agreement announced on December 14, 2020. The authorization is based on the totality of scientific evidence shared by the Company, including a data analysis from the pivotal Phase 3 clinical study announced on November 30, 2020.

Moderna has also received authorization for its COVID-19 vaccine from health agencies in the United States, Canada, Israel, the European Union, the United Kingdom and Switzerland. Additional authorizations are currently under review in other countries and by the World Health Organization.